Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia

European Respiratory Journal

Volumn 29, Issue 4, 2007, Pages 751-756

  Menendez R ^a   Reyes, S ^a,b   Martinez R ^a   de la Cuadra, P ^a   Vallés, J Manuel ^a   Vallterra, J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cost effectiveness; Mortality; Pneumonia; Readmission; Treatment guidelines

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD ANALYSIS; CLINICAL FEATURE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DIAGNOSTIC TEST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPAIN;

AGED; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; ECONOMICS, MEDICAL; FEMALE; GUIDELINES; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPAIN;

EID: 34147147052     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00052506     Document Type: Article

References (37)

1. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: 61-66.
2. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165: 766-772.
3. Lave JR, Fine MJ, Sankey SS, Hanusa BH, Weissfeld LA, Kapoor WN. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas. J Gen Intern Med 1996; 11: 415-421.
4. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997; 10: 1530-1534.
5. Monge V, San-Martin VM, Gonzalez A. The burden of community-acquired pneumonia in Spain. Eur J Public Health 2001; 11: 362-364.
6. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000; 109: 378-385.
7. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
8. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722-727.
9. Siegel RE. Strategies for early discharge of the hospitalized patient with community-acquired pneumonia. Clin Chest Med 1999; 20: 599-605.
10. Weingarten S, Riedinger MS, Sandhu M, et al. Can practice guidelines safely reduce hospital length of stay? Results from a multicenter interventional study. Am J Med 1998; 105: 33-40.
11. Metersky ML, Tate JP, Fine MJ, Petrillo MK, Meehan TP. Temporal trends in outcomes of older patients with pneumonia. Arch Intern Med 2000; 160: 3385-3391.
12. Menéndez R, Ferrando D, Valles JM, Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest 2002; 122: 612-617.
13. Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110: 451-457.
14. Nathwani D, Rubinstein E, Barlow G, Davey P. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis 2001; 32: 728-741.
15. Frias J, Gomis M, Prieto J, et al. [Initial empirical antibiotic treatment of community-acquired pneumonia]. Rev Esp Quimioter 1998; 11: 255-261.
16. Dorca J, Bello S, Blanquer J, et al. [The diagnosis and treatment of community-acquired pneumonia. SEPAR. Sociedad Española de Neumología y Cirugía Torácica]. Arch Bronconeumol 1997; 33: 240-246.
17. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
18. Diari Oficial de la Generalitat Valenciana. www.docv.gva.es/portal/ portal/2002/12/31/pdf/doc/2002_14538.pdf. 30 Date last updated: December 31 2002. Date last accessed: May 31 2003.
19. Campbell MK, Torgerson DJ. Bootstrapping: estimating nfidence intervals for cost-effectiveness ratios. QJM 1999; 92: 177-182.
20. Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004; 117: 726-731.
21. Menéndez R, Torres A, Zalacain R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005; 172: 757-762.
22. Marras TK, Chan CK. Use of guidelines in treating community-acquired pneumonia. Chest 1998; 113: 1689-1694.
23. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458-1465.
24. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-2572.
25. Menéndez R, Torres A, Rodríguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783-1790.
26. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001; 10: 179-184.
27. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147-154.
28. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1172-1177.
29. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired Pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749-755.
30. Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998; 158: 1350-1356.
31. Ramírez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-2454.
32. Weingarten SR, Riedinger MS, Hobson P, et al. Evaluation of a pneumonia practice guideline in an interventional trial. Am J Respir Crit Care Med 1996; 153: 1110-1115.
33. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278: 32-39.
34. Gilbert K, Gleason PP, Singer DE, et al. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. Am J Med 1998; 104: 17-27.
35. Meehan TP, Weingarten SR, Holmboe ES, et al. A statewide initiative to improve the care of hospitalized pneumonia patients: The Connecticut Pneumonia Pathway Project. Am J Med 2001; 111: 203-210.
36. Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines. Pharmacoeconomics 2004; 22: 751-757.
37. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005; 128: 2238-2246.